{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T01:41:29Z","timestamp":1766367689207,"version":"3.48.0"},"reference-count":25,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nonalcoholic fatty liver disease (NAFLD) is characterized by excessive hepatic fat accumulation and is closely associated with obesity, diabetes, and hyperlipidemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study explores the effects of pachymaran on NAFLD induced by a high-fat diet (HFD) in a murine model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Thirty male C57BL\/6 mice were allocated into five groups: normal diet (ND), NAFLD, and high-, medium-, and low-dose pachymaran (200, 100, and 50\u2009mg\/kg, respectively). All groups except the ND were fed a HFD to induce NAFLD. The pachymaran groups received daily intragastric pachymaran for eight weeks. Post-treatment, liver weight were recorded, serum indices assessed, and hepatic pathology evaluated via histological and Oil Red O staining. Adenylate-activated protein kinase (AMPK) gene expression was analyzed through western blotting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The body weight and liver gain (87.8 and 23.0%) in the high-dose pachymaran group were significantly less than those (154.2 and 82.0%) in the NAFLD group (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.05). Fat content and serum indices improvements correlated with increased pachymaran doses. Histological analyses indicated significant alleviation of hepatocyte hypertrophy and ballooning steatosis in treated groups. Oil Red O staining confirmed a substantial decrease in hepatic lipid droplets, and western blot results indicated a significant increase in AMPK phosphorylation following treatment (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pachymaran effectively mitigated fat accumulation, hepatocyte degeneration, and injury in mice with diet-induced NAFLD, likely through modulation of the AMPK pathway.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/med-2025-1241","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T08:59:13Z","timestamp":1753347553000},"source":"Crossref","is-referenced-by-count":0,"title":["Pachymaran alleviates fat accumulation, hepatocyte degeneration, and injury in mice with nonalcoholic fatty liver disease"],"prefix":"10.1515","volume":"20","author":[{"given":"Hong","family":"Yu","sequence":"first","affiliation":[{"name":"Medical Laboratory, Wuhan Hospital of Traditional Chinese Medicine , Wuhan , Hubei, 430050 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Wan","sequence":"additional","affiliation":[{"name":"Medical Laboratory, Wuhan Hospital of Traditional Chinese Medicine , Wuhan , Hubei, 430050 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Li","sequence":"additional","affiliation":[{"name":"Medical Laboratory, Wuhan Hospital of Traditional Chinese Medicine , Wuhan , Hubei, 430050 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing","family":"Liu","sequence":"additional","affiliation":[{"name":"Medical Laboratory, Wuhan Hospital of Traditional Chinese Medicine , No. 303, Sixin Avenue, Hanyang District , Wuhan , Hubei, 430050 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"2025122201305415552_j_med-2025-1241_ref_001","doi-asserted-by":"crossref","unstructured":"Abdelmalek MF. Nonalcoholic fatty liver disease: Another leap forward. Nat Rev Gastroenterol Hepatol. 2021;18(2):85\u20136.","DOI":"10.1038\/s41575-020-00406-0"},{"key":"2025122201305415552_j_med-2025-1241_ref_002","doi-asserted-by":"crossref","unstructured":"Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism. 2019;92:82\u201397.","DOI":"10.1016\/j.metabol.2018.11.014"},{"key":"2025122201305415552_j_med-2025-1241_ref_003","doi-asserted-by":"crossref","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328\u201357.","DOI":"10.1002\/hep.29367"},{"key":"2025122201305415552_j_med-2025-1241_ref_004","doi-asserted-by":"crossref","unstructured":"Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: The state of the disease. Gastroenterology. 2020;158(7):1851\u201364.","DOI":"10.1053\/j.gastro.2020.01.052"},{"key":"2025122201305415552_j_med-2025-1241_ref_005","doi-asserted-by":"crossref","unstructured":"Zhou J, Zhou F, Wang W, Zhang XJ, Ji YX, Zhang P, et al. Epidemiological features of NAFLD from 1999 to 2018 in China. Hepatology. 2020;71(5):1851\u201364.","DOI":"10.1002\/hep.31150"},{"key":"2025122201305415552_j_med-2025-1241_ref_006","doi-asserted-by":"crossref","unstructured":"Fang J, Yu CH, Li XJ, Yao JM, Fang ZY, Yoon SH, et al. Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications. Front Cell Infect Microbiol. 2022;12:997018.","DOI":"10.3389\/fcimb.2022.997018"},{"key":"2025122201305415552_j_med-2025-1241_ref_007","doi-asserted-by":"crossref","unstructured":"Rong L, Zou J, Ran W, Qi X, Chen Y, Cui H, et al. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front Endocrinol (Lausanne). 2022;13:1087260.","DOI":"10.3389\/fendo.2022.1087260"},{"key":"2025122201305415552_j_med-2025-1241_ref_008","doi-asserted-by":"crossref","unstructured":"Zhou JH, Cai JJ, She ZG, Li HL. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice. World J Gastroenterol. 2019;25(11):1307\u201326.","DOI":"10.3748\/wjg.v25.i11.1307"},{"key":"2025122201305415552_j_med-2025-1241_ref_009","doi-asserted-by":"crossref","unstructured":"Li X, He Y, Zeng P, Liu Y, Zhang M, Hao C, et al. Molecular basis for Poria cocos mushroom polysaccharide used as an antitumour drug in China. J Cell Mol Med. 2019;23(1):4\u201320.","DOI":"10.1111\/jcmm.13564"},{"key":"2025122201305415552_j_med-2025-1241_ref_010","doi-asserted-by":"crossref","unstructured":"Li W, Yu J, Zhao J, Xiao X, Li W, Zang L, et al. Poria cocos polysaccharides reduces high-fat diet-induced arteriosclerosis in ApoE(\u2212\/\u2212) mice by inhibiting inflammation. Phytother Res. 2021;35(4):2220\u20139.","DOI":"10.1002\/ptr.6980"},{"key":"2025122201305415552_j_med-2025-1241_ref_011","doi-asserted-by":"crossref","unstructured":"Wu K, Fan J, Huang X, Wu X, Guo C. Hepatoprotective effects exerted by Poria Cocos polysaccharides against acetaminophen-induced liver injury in mice. Int J Biol Macromol. 2018;114:137\u201342.","DOI":"10.1016\/j.ijbiomac.2018.03.107"},{"key":"2025122201305415552_j_med-2025-1241_ref_012","doi-asserted-by":"crossref","unstructured":"Liu F, Zhang L, Feng X, Ibrahim SA, Huang W, Liu Y. Immunomodulatory activity of carboxymethyl pachymaran on immunosuppressed mice induced by cyclophosphamiade. Molecules. 2021;26(19):5733.","DOI":"10.3390\/molecules26195733"},{"key":"2025122201305415552_j_med-2025-1241_ref_013","doi-asserted-by":"crossref","unstructured":"Garcia D, Hellberg K, Chaix A, Wallace M, Herzig S, Badur MG, et al. Genetic liver-specific AMPK activation protects against diet-induced obesity and NAFLD. Cell Rep. 2019;26(1):192\u2013208.e196.","DOI":"10.1016\/j.celrep.2018.12.036"},{"key":"2025122201305415552_j_med-2025-1241_ref_014","doi-asserted-by":"crossref","unstructured":"Chyau CC, Wang HF, Zhang WJ, Chen CC, Huang SH, Chang CC, et al. Antrodan alleviates high-fat and high-fructose diet-induced fatty liver disease in C57BL\/6 mice model via AMPK\/Sirt1\/SREBP-1c\/PPAR\u03b3 pathway. Int J Mol Sci. 2020;21(1):360.","DOI":"10.3390\/ijms21010360"},{"key":"2025122201305415552_j_med-2025-1241_ref_015","doi-asserted-by":"crossref","unstructured":"Liang W, Menke AL, Driessen A, Koek GH, Lindeman JH, Stoop R, et al. Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology. PLoS One. 2014;9(12):e115922.","DOI":"10.1371\/journal.pone.0115922"},{"key":"2025122201305415552_j_med-2025-1241_ref_016","doi-asserted-by":"crossref","unstructured":"Pouwels S, Sakran N, Graham Y, Leal A, Pintar T, Yang W, et al. Non-alcoholic fatty liver disease (NAFLD): A review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022;22(1):63.","DOI":"10.1186\/s12902-022-00980-1"},{"key":"2025122201305415552_j_med-2025-1241_ref_017","doi-asserted-by":"crossref","unstructured":"Ioannou GN. The role of cholesterol in the pathogenesis of NASH. Trends Endocrinol Metab. 2016;27(2):84\u201395.","DOI":"10.1016\/j.tem.2015.11.008"},{"key":"2025122201305415552_j_med-2025-1241_ref_018","doi-asserted-by":"crossref","unstructured":"Musso G, Gambino R, Cassader M. Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog Lipid Res. 2013;52(1):175\u201391.","DOI":"10.1016\/j.plipres.2012.11.002"},{"key":"2025122201305415552_j_med-2025-1241_ref_019","doi-asserted-by":"crossref","unstructured":"Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212\u201324.","DOI":"10.1016\/S0140-6736(20)32511-3"},{"key":"2025122201305415552_j_med-2025-1241_ref_020","doi-asserted-by":"crossref","unstructured":"Arab JP, Arrese M, Trauner M. Recent insights into the pathogenesis of nonalcoholic fatty liver disease. Annu Rev Pathol. 2018;13:321\u201350.","DOI":"10.1146\/annurev-pathol-020117-043617"},{"key":"2025122201305415552_j_med-2025-1241_ref_021","doi-asserted-by":"crossref","unstructured":"Maurice J, Manousou P. Non-alcoholic fatty liver disease. Clin Med (Lond). 2018;18(3):245\u201350.","DOI":"10.7861\/clinmedicine.18-3-245"},{"key":"2025122201305415552_j_med-2025-1241_ref_022","doi-asserted-by":"crossref","unstructured":"Lee JH, Baek SY, Jang EJ, Ku SK, Kim KM, Ki SH, et al. Oxyresveratrol ameliorates nonalcoholic fatty liver disease by regulating hepatic lipogenesis and fatty acid oxidation through liver kinase B1 and AMP-activated protein kinase. Chem Biol Interact. 2018;289:68\u201374.","DOI":"10.1016\/j.cbi.2018.04.023"},{"key":"2025122201305415552_j_med-2025-1241_ref_023","doi-asserted-by":"crossref","unstructured":"Long JK, Dai W, Zheng YW, Zhao SP. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1\/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease. Mol Med. 2019;25(1):26.","DOI":"10.1186\/s10020-019-0085-2"},{"key":"2025122201305415552_j_med-2025-1241_ref_024","doi-asserted-by":"crossref","unstructured":"Chauhan AS, Liu X, Jing J, Lee H, Yadav RK, Liu J, et al. STIM2 interacts with AMPK and regulates calcium-induced AMPK activation. Faseb J. 2019;33(2):2957\u201370.","DOI":"10.1096\/fj.201801225R"},{"key":"2025122201305415552_j_med-2025-1241_ref_025","doi-asserted-by":"crossref","unstructured":"Li R, Li Y, Yang X, Hu Y, Yu H, Li Y. Reducing VEGFB accelerates NAFLD and insulin resistance in mice via inhibiting AMPK signaling pathway. J Transl Med. 2022;20(1):341.","DOI":"10.1186\/s12967-022-03540-2"}],"container-title":["Open Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2025-1241\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2025-1241\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T01:39:00Z","timestamp":1766367540000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/med-2025-1241\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,6,9]]},"published-print":{"date-parts":[[2025,6,9]]}},"alternative-id":["10.1515\/med-2025-1241"],"URL":"https:\/\/doi.org\/10.1515\/med-2025-1241","relation":{},"ISSN":["2391-5463"],"issn-type":[{"type":"electronic","value":"2391-5463"}],"subject":[],"published":{"date-parts":[[2025,1,1]]},"article-number":"20251241"}}